Brian Druker
布莱恩·德鲁克
MD
Director, OHSU Knight Cancer InstituteOHSU奈特癌症研究所所长
👥Biography 个人简介
Brian Druker is the founding father of modern targeted cancer therapy, having driven the clinical development of imatinib (Gleevec) for CML. His work transformed a once-fatal leukemia into a manageable chronic condition and established the paradigm of oncogene-targeted drug development.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Imatinib Clinical Development for CML
Led clinical trials establishing imatinib as the standard of care for BCR-ABL-positive CML, achieving >80% durable remission rates and transforming patient outcomes.
Oncogene Addiction Concept Validation
Provided seminal clinical evidence for oncogene addiction in cancer, demonstrating that tumors driven by a single kinase mutation remain dependent on it, validating targeted therapy.
Representative Works 代表性著作
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
New England Journal of Medicine (2001)
Pivotal clinical trial establishing imatinib's dramatic efficacy in CML, leading to FDA approval and defining the era of molecularly targeted oncology.
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in blast crisis of chronic myeloid leukemia
New England Journal of Medicine (2001)
Demonstrated imatinib activity in advanced CML, confirming BCR-ABL as the key driver and reinforcing the targeted therapy paradigm across cancer types.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Sebastian Bauer
University Hospital Essen (Universitätsklinikum Essen)
Suzanne George
Dana-Farber Cancer Institute / Harvard Medical School
Marcia S. Brose
Sidney Kimmel Cancer Center, Thomas Jefferson University
Lori J. Wirth
Massachusetts General Hospital, Harvard Medical School
关注 布莱恩·德鲁克 的研究动态
Follow Brian Druker's research updates
留下邮箱，当我们发布与 Brian Druker（Oregon Health & Science University）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment